Although no additional JAK2 mutations have been detected thus far in MPN patients undergoing JAK2 inhibitor treatment, results of several in vitro studies suggest that JAK2 inhibitors may in fact be prone to resistance mediated by novel point mutations in JAK2 itself as well as through activation of other pathways [22-26]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.